A Phase 1 Study of SY-1365 in Adult Patients With Advanced Solid Tumors


This study will consist of two parts. Part 1 is a dose-escalation/safety evaluation to provisionally identify a dose and regimen of SY-1365 for further evaluation in Part 2. Approximately 35 patients with advanced solid tumors will be enrolled into Part 1 of the study. Following the identification of a recommended dose and regimen from Part 1, the study will enter Part 2 to further evaluate safety and the antitumor activity of SY-1365 in patients with select solid tumors, and to confirm target engagement and downstream pathway impact in patients with any solid tumor histology. Part 2 will consist of two cohorts: - Cohort 1: approximately 25 patients with small cell lung cancer (SCLC), triple negative breast cancer (TNBC), or ovarian cancer (OC) - Cohort 2: approximately 10 patients with biopsy-accessible, advanced solid tumors of any histology

Study Start Date

May, 12 2017

Estimated Completion Date

November 2019


  • Drug: SY-1365

Study ID

Syros Pharmaceuticals -- SY-1365-101



Trial ID


Study Type


Trial Phase

Phase 1

Enrollment Quota



Syros Pharmaceuticals

Inclusion Criteria

  • 18 years of age or older
  • Disease status
  • Part 1: any histologically-confirmed metastatic or unresectable solid tumor for which standard curative or palliative measures do not exist or are no longer effective
  • Part 2, Cohort 1: histologically-confirmed diagnosis of SCLC, TNBC, or ovarian cancer (high-grade serous type) for which standard curative or palliative measures do not exist or are no longer effective
  • Part 2, Cohort 2: any histologically-confirmed metastatic or unresectable solid tumor for which standard curative or palliative measures do not exist or are no longer effective
  • At least 1 measurable lesion by RECIST 1.1
  • Prior treatment (Part 2, Cohort 1 only)
  • SCLC: must have received prior platinum doublet therapy
  • TNBC: must have received prior taxane therapy
  • Ovarian Cancer (high-grade serous type): must have received prior platinum doublet therapy, and in the opinion of the Investigator is unlikely to benefit from additional lines of platinum-based therapy
  • Part 2 Cohort 2 only
  • Must have accessible tumor tissue and be willing to undergo tumor tissue sampling (biopsies/aspirates) pre
  • and post-treatment
  • All toxicities (except alopecia) from prior cancer treatments must have resolved to ? Grade 1 or returned to baseline levels prior to enrollment
  • Eastern Cooperative Oncology Group (ECOG) performance status of 0-2
  • Life expectancy > 3 months
  • absolute neutrophil count: ? 1.5 x 109/L
  • platelets: ? 100 x 109/L
  • hemoglobin: ? 9 g/dL
  • total bilirubin ? 1.5 institutional upper limit of normal [ULN])
  • AST (SGOT)/ ALT (SGPT): ? 3.0 x institutional ULN
  • Creatinine ? 1.5 x institutional ULN OR creatinine clearance ? 60 mL/min by Crockoft-Gault for participants with creatinine levels above institutional normal
  • Negative pregnancy test for women of child bearing potential

Exclusion Criteria

  • Chemotherapy or limited field radiotherapy within 2 weeks, wide field radiotherapy within 4 weeks, or nitrosoureas or mitomycin C within 6 weeks prior to entering the study
  • Major surgery within 2 weeks of starting the study treatment, or not recovered to baseline status from the effects of surgery received > 2 weeks prior
  • Received any other investigational agents within 4 weeks prior to enrollment, or < 5 half-lives since completion of previous investigational therapy, whichever is shorter
  • Received previous non-cytotoxic, FDA-approved anticancer agent within previous 2 weeks, or < 5 half-lives since completion of previous therapy, whichever is shorter
  • Prior exposure to transcriptional kinase family CDK inhibitors, such as the CDK7 and CDK9 inhibitors alvocidib (Flavopiridol), dinaciclib, and seliciclib. Exception: previous exposure to cell cycle CDK inhibitors such as CDK4 and CDK6 (eg, palbociclib) is allowed
  • Known brain metastases or carcinomatous meningitis. Exception: previously treated brain metastatic disease that remains stable on MRI ? 4 weeks prior to enrollment, without steroids or anti-epileptic medications
  • History of allergic reactions attributed to compounds of similar chemical composition to SY-1365
  • Immunocompromised patients with increased risk of opportunistic infections, including known HIV-positive patients
  • Patients with known active Hepatitis B or Hepatitis C infection
  • Prior treatment (< 2 weeks before start of SY-1365) with moderate or strong CYP3A4 inducers or strong CYP3A4 inhibitors. See list in Appendix 3
  • Baseline QT interval corrected with Fridericia's method (QTcF) > 480 ms




18 Years and older

Accepts Healthy Volunteers


Study Locations and Contact Information (2)

Study Location Distance Name Phone Email
Dana Farber Cancer Institute - Boston, Massachusetts 2.4 miles None None None
South Texas Accelerated Research Therapeutics - San Antonio, Texas 1,768.2 miles None None None

ClinicalTrialsLocator.com provides clinical trial listings in an easy to view format. All clinical trial information is pulled directly from ClinicalTrials.gov. This website does not guarantee acceptance into any clinical trial, and is not responsible for adverse events that may be incurred from a clinical trial.